Sequenta is a venture-backed company dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT(TM) platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/02/13 | $20,000,000 | Series C |
Foresite Capital Management Index Ventures Mohr Davidow Ventures | undisclosed |
| 10/20/14 | undisclosed | Strategic |
Celgene Corporation | undisclosed |
